After A Year Of Prevnar Shortages, Wyeth Enters 2005 With Inventory On-Hand
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth enters 2005 with "significant" Prevnar inventory, the company said during a quarterly earnings call Jan. 31
You may also be interested in...
Adult Pneumococcal Vaccinations Could Increase Under CDC Program
The Centers for Disease Control & Prevention is awarding a two-year contract to evaluate whether a proactive pharmacist pneumococcal vaccination program would increase adult use of the vaccine. Merck’s Pneumovax 23 is the only pneumococcal vaccine commercially available for adults.
Adult Pneumococcal Vaccinations Could Increase Under CDC Program
The Centers for Disease Control & Prevention is awarding a two-year contract to evaluate whether a proactive pharmacist pneumococcal vaccination program would increase adult use of the vaccine. Merck’s Pneumovax 23 is the only pneumococcal vaccine commercially available for adults.
Prevnar, Effexor, Enbrel Powering Strong First Quarter For Wyeth
Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.